Abstract
Bone tissue regeneration remains a critical research focus in biomedical tissue engineering. Icariin, a flavonoid compound extracted from the medicinal herb Epimedium, has been traditionally used in Chinese medicine to treat bone-related disorders such as lumbago associated with kidney Yang deficiency, impotence, and musculoskeletal weakness. Recent advances in biomedical research have increasingly clarified its biological mechanisms, revealing that icariin can promote osteoblast proliferation and differentiation while simultaneously inhibiting osteoclast activity. However, current application of icariin in biomedical tissue engineering remains in the exploratory phase, with its molecular mechanisms not yet fully characterized. Moreover, the in vivo and in vitro evaluation systems for its therapeutic efficacy and safety remain to be optimized. A comprehensive investigation into icariin's osteogenic properties and its translational potential in biomedical tissue engineering are warranted. Such investigations may provide a theoretical basis and experimental evidence for developing novel bone repair materials and therapeutic strategies, offering substantial scientific significance and clinical application value.